Medtronic CEO Omar Ishrak has signaled that executives have to meet his strict criteria on acquisitions, but he may have to relax the rule in one product group. One analyst believes that to cement its leading position in a therapy that treats patients with uncontrolled hypertension, the Minnesota device maker will likely have to make an acquisition. Right now, Medtronic is ahead of the pack in the field of renal denervation. Its Simplicity renal denervation system is approved in Europe and patients are being enrolled in a U.S. clinical trial.
